Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2020, with a specific transaction date of December 21, 2020. The report serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a disclosure of an insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of notional ADSs |
| Instrument | American Depositary Shares (ADSs) |
| Price per ADS | $36.2200 |
| Volume | 1,150.600 ADSs |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction within Dr. Barron's GSK Executive Supplemental Savings Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory notification of a specific securities transaction.
Key Facts for Investor Verification
- Insider Identity: Dr. H Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: Acquisition of notional ADSs via an executive savings plan, not a direct open-market purchase.
- Transaction Date: December 21, 2020.
- Financial Impact: The filing does not disclose the total monetary value of the transaction, only the unit price and volume.